↓ Skip to main content

Dove Medical Press

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

Overview of attention for article published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, July 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

policy
1 policy source
twitter
3 X users
patent
6 patents
wikipedia
4 Wikipedia pages

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
73 Mendeley
Title
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
Published in
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, July 2012
DOI 10.2147/dmso.s21979
Pubmed ID
Authors

Fei Wang, Justine Surh, Manmeet Kaur

Abstract

Insulin degludec (IDeg) is a neutral, ultralong-acting new generation basal insulin analog developed by NovoNordisk currently in Phase III clinical development. IDeg offers a duration of action of more than 42 hours in adults, much longer than current basal insulin formulations.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Malaysia 1 1%
India 1 1%
Unknown 71 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 18%
Student > Ph. D. Student 12 16%
Researcher 8 11%
Student > Postgraduate 8 11%
Student > Doctoral Student 5 7%
Other 19 26%
Unknown 8 11%
Readers by discipline Count As %
Medicine and Dentistry 30 41%
Biochemistry, Genetics and Molecular Biology 8 11%
Pharmacology, Toxicology and Pharmaceutical Science 6 8%
Agricultural and Biological Sciences 4 5%
Chemistry 3 4%
Other 11 15%
Unknown 11 15%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2022.
All research outputs
#2,039,127
of 25,373,627 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#92
of 1,180 outputs
Outputs of similar age
#12,165
of 176,748 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#2
of 10 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,180 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,748 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.